Caricamento quotazioni...
Previsioni
| Acquista |
1 |
| Mantieni |
0 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
Lonza appoints Samanta Cimitan as chief commercial officer
Lonza will appoint Samanta Cimitan as chief commercial officer, senior vice president and member of the extended executive committee no later than Jan. 1, 2027. Cimitan joins from Celonic, where she is currently CEO, and previously spent almost 13 years at Lonza in various strategy and sales roles. In the newly created role she will standardize customer service, global marketing, market access and commercial management across all business units and lead the management of strategic customers. » Altro su finanzen.net
Lonza shares fall after revenue miss despite strong margins
Lonza shares lost 2.2% after reporting H1 2026 results, after revenue slightly missed consensus estimates. Core EBITDA rose currency-adjusted by 27.4% to around CHF 1.18bn and profit from continuing operations increased by 44%. The company raised its core EBITDA margin guidance for 2026 to 33–34%, but this did not fully offset the revenue disappointment. Negative market sentiment and a “buy the rumor, sell the news” reaction amplified the short-term price setback. » Altro su de.investing.com
Lonza reports production expansion and US partnership ahead of half-year report
Lonza's stock has recently staged a strong comeback, supported by sector rotation and positive company news. At the end of June, Lonza announced it will expand production of payload linkers in Visp (commissioning in 2028) and broadened a US cooperation to produce two active pharmaceutical ingredients (APIs) with an option for two more, a move that could potentially generate billions in revenue. Analyst consensus sees revenue growth of around 16.5% for H1 2026 and a significantly higher core-EBITDA margin; CEO Wolfgang Wienand and CFO Philippe Deecke will comment on the half-year results in a conference call. » Altro su finanzen.net
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 3,66Mld | - |
| Utile lordo | 1,40Mld | - |
| Utile netto | 640,26M | - |
| EBITDA | 1,24Mld | - |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 43,83Mld€ |
Numero di azioni | 69,84M |
Massimo/minimo a 52 settimane | 641,73€ - 329,36€ |
Rendimento da dividendo | 0,87% |
Dividendi TTM | 5,47€ |
Beta | 0,84 |
Rapporto P/E | −381,56 |
Rapporto PEG | 2,38 |
Rapporto P/B | 5,05 |
Rapporto P/S | 6,48 |
Profilo aziendale
Lonza Group AG bietet Produkte und Dienstleistungen für den Pharma-, Biotech- und Ernährungsmarkt in der Schweiz und international an. Das Unternehmen ist in den Geschäftsbereichen Biologics, Small Molecules, Cell and Gene sowie Capsules and Health Ingredients tätig. Der Geschäftsbereich Biologics befasst sich mit der Auftragsentwicklung und -herstellung von Biopharmazeutika. Der Geschäftsbereich Small Molecules ist als integrierter Entwicklungs- und Produktionsdienstleister für kleinmolekulare Wirkstoffe und deren Zwischenprodukte tätig. Der Geschäftsbereich Zell- und Gentherapie entwickelt Technologien und Plattformen, die die Herstellungsprozesse und die Produktion von Zell- und Gentherapien industrialisieren. Darüber hinaus bietet er Auftragsentwicklungs- und -herstellungsdienstleistungen für eine Reihe von allogenen und autologen Zelltherapien und Exosom-basierten Therapien sowie viralen Vektor-Gentherapien an. Dieses Segment bietet Spezialrohstoffe und technologische Lösungen für Zell- und Gentherapien, injizierbare Arzneimittel, Impfstoffe und Bioproduktionsmärkte. Der Geschäftsbereich Capsules and Health Ingredients bietet Kapseln, Darreichungsformen und Inhaltsstoffe für pharmazeutische und nutrazeutische Kunden an. Lonza Group AG wurde 1897 gegründet und hat ihren Hauptsitz in Basel, Schweiz.
| Nome | LONZA |
| CEO | Wolfgang Wienand |
| Sede centrale | Basel,
bw Svizzera |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 01/11/1999 |
| Dipendenti | 16.866 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Pnk | LZAGF |
London Stock Exchange | 0QNO.L |
SIX | LONN.SW |
Düsseldorf | LO3.DU |
Hamburg | LO3.HM |
London | 0QNO.L |
München | LO3.MU |
Scopri gli asset
Gli azionisti di LONZA investono anche nei seguenti asset

